Alkame Technology Begins Aquaculture Testing In Colorado

Las Vegas, NV (Marketwired) - Alkame Holdings, Inc. (OTCQB: ALKM), a publicly traded health and wellness technology holding company with a focus on patentable, innovative, and eco-friendly products announced today that High Country Shrimp LLC, the Company's wholly owned subsidiary, has secured a location and begun testing for the company's 'proof of concept,' utilizing the patented Alkame technology for use within the aquaculture industry.

Testing is underway and in full swing now in Wellington Colorado, an ideal location for Alkame and High Country to develop a "proof-of-concept" application for the technology, with its unique patented water treatment system incorporated into an intensive indoor aquaculture farming process. With the Alkame Water micro-clustered structure, increased oxygenation, and proper pH levels, Alkame testing is expected to provide successful concrete and verifiable information that the technology provides significant benefits, which can be implemented across the aquaculture industry as a whole for all freshwater species.

Overseeing the testing process is 40 year aquaculture veteran, Jim Keeton, who stated, "In order to achieve optimal growth, maintenance and harvest conditions, microbiological support will be a critical component of the studies success. Alkame's technology is being tested to access changes or improvement in water quality, effect on bio floc, ammonia, nitrite, and nitrate reduction through consistent observation, maintenance, and investigation. This will allow us to develop proprietary growing procedures, different and more valuable, through use of this unique technology than the industry standards, essentially putting Alkame ahead of the competition on many fronts."

"This would be a major coupe within the industry, both from a strategic and an economic stand point," stated Alkame Holdings CEO, Robert Eakle. He added, "Staying true to our word, we've been aggressively exploring the other uses for our water treatment technology. This will enable us to both diversify our portfolio of products, as well as begin implementation of our unique system into many different new and exciting applications. We plan to show this 'proof of concept' to the aquaculture world very shortly. It's just a tremendous opportunity to enter this particular industry with real data on the use of our patented technology for intensive aquaculture farming," Eakle continues.

About Alkame Holdings, Inc.
Alkame Holdings, Inc. is a publicly traded health and wellness technology holding company, with a focus on patentable, innovative, and eco-friendly consumer products. The Company's wholly-owned subsidiaries market and distribute enhanced waters utilizing an exclusive patented formula and technology to create water with several unique properties, enabling an increase to available oxygen content, optimized pH levels, as well as the added benefits of electrolytes, and enhancement of antioxidant properties, equating into many potential health benefits, such as a reduced structure for permeability, improved metabolic efficiency, a boosted immune system, improved cardio respiratory function, and a decrease in lactic acid for faster muscle recovery. The organization is diligently building a strong foundation through the launch and acquisition of appropriate business assets, and by pursuing multiple applications to utilize its Intellectual Property by placement into several emerging business sectors, such as the growing aqua-culture industry, consumer bottled water and RTD products, household pet products, horticulture and agriculture applications, as well as many other various water treatment solutions to both new and existing business platforms.

For more information, visit www.alkamewater.com.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Tops Markets will achieve significant additional distribution for the Company's products, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.